Read more about FDA Approves Rucaparib as Maintenance Treatment for Platinum Sensitive Recurrent Ovarian Cancer
Apr 10, 2018
FDA Approves Rucaparib as Maintenance Treatment for Platinum Sensitive Recurrent Ovarian Cancer
...statistically significant difference between the drug and the placebo, regardless of BRCA status. “Both the efficacy and safety results from the ARIEL3 study reinforce the important role of Rubraca (rucaparib)...